Zelira Therapeutics (AU:ZLD) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Zelira Therapeutics is gearing up to present its latest business advancements at the Automic Invest 2024 conference, highlighting its successful proprietary cannabinoid medications like HOPE® and ZENIVOL®. With a robust pipeline and strategic partnerships, Zelira is expanding its market presence in the US, Australia, and Germany, aiming for significant growth in the global cannabinoid-based medicine sector.
For further insights into AU:ZLD stock, check out TipRanks’ Stock Analysis page.